MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12020-023-03580-8

Медицинская библиотека · Endocrine · 2023

Practical recommendations for antihypertensive therapy during the primary aldosteronism screening test.

Li Jialin, Yan Hongzhou, Li Ling, Lin Xiuwen, Zhao Zheng, Zhou Cheng, Zhang Qi

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The aldosterone-to-renin activity ratio (ARR) is recommended as a screening test for primary aldosteronism (PA). The use of antihypertensive medication is one of the most important factors to take into account when interpreting the ARR.

OBJECTIVES

The goal of this study was to compare the effect of various antihypertensive drug classes on biochemical testing and provide practical recommendations for antihypertensive medication regimens in patients suspected of having PA.

METHODS

We retrospectively investigated 4218 hypertensive patients who underwent PA detection between January 2020 and February 2023. Finally, 25 patients with essential hypertension (EH) and 39 with PA were involved. The enrolled EH patients were selected from EH patients with at least two screening tests with interfering medication changes for at least 4 weeks.

RESULTS

A total of 2/18 (11.1%) EH patients had opposite screening results after angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), dihydropyridine-calcium channel blockers (DHP-CCBs) and diuretics were withdrawn. A total of 3/3 (100%) of the patients were initially screened as positive but had results that tested negative after β-blockers withdrawal. A total of 3/39 (7.7%) PA patients were misdiagnosed with EH with drug effects. Only plasma renin activity was markedly reduced after antihypertensive medication washout (P = 0.0173).

CONCLUSIONS

Not every patient receiving β-blockers, ACEIs, ARBs and DHP-CCBs with negative reports needed withdrawal or switching antihypertensive drugs. We recommend that patients be left on a regimen that includes β-blockers, ACEIs, ARBs, DHP-CCBs and spironolactone when determining the ARR during the initial test.

Для цитирования: Li Jialin, Yan Hongzhou, Li Ling, Lin Xiuwen, Zhao Zheng, Zhou Cheng, Zhang Qi. Practical recommendations for antihypertensive therapy during the primary aldosteronism screening test.. Endocrine. 2023. DOI: 10.1007/s12020-023-03580-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.